JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2021. Vol. 66. № 4. P. 13–17
Comparative Evaluation оf the Anti-Radiation Efficacy of Flagellin
by Survival and Micronucleus Test
N.I. Lisina, K.Yu. Romanova, L.P. Sycheva, L.M. Rozhdestvensky
A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Contact person: Nina Ivanovna Lisina: This email address is being protected from spambots. You need JavaScript enabled to view it.
ABSTRACT
Purpose: Comparative evaluation of the effectiveness of the domestic drug flagellin (development of the State Research Institute of High-Purity Biological Products, St. Petersburg) in an extended range of drug administration periods before and after irradiation, as well as evaluation of the possibility of using the micronucleus test as a biomarker of its effectiveness.
Material and methods: The work was performed on male ICR CD1 mice weighing 20–22g. The radioprotective effectiveness of flagellin was evaluated by the 30-day survival rate of experimental animals in comparison with control groups. The cytogenetic effect was evaluated by a micronucleus test in polychromatophilic erythrocytes (MJ-PCE) of mouse bone marrow. Irradiation was performed on the RUST M1 X-unit at a dose rate of 1.1 Gy/min in the dose range from 7 to 10 Gy for survival assessment and at a dose of 1 Gy for the micronucleus test. Flagellin was administered intraperitoneally at 0.2 mg/kg for 18 h and 30 min before irradiation, 10 and 30 min after irradiation. The animals of the control groups were injected with a solvent – phosphate-albumin buffer at the same time and in the same volume.
Results: The most effective was the use of flagellin for 30 min and 10 min in relation to radiation (survival at 8.5 Gy 92 % and 78 %, at 9 Gy 81 % and 55 %, respectively) with survival in the control 29 % and 0. In the most studied version of the introduction of flagellin 30 minutes before exposure, the FID values at the level of generally accepted estimates LD16, LD50, LD84, were 1.3; 1.2 and 1.2, respectively.
Conclusions: It is of interest to further expand the time range of the use of flagellin, especially after irradiation. The use of the method of estimating the proportion of polychromatophilic erythrocytes with micronuclei in the bone marrow allowed us to identify the optimal timing of drug administration much faster than in terms of survival (MJ-PCR test was performed 24 hours after irradiation). The MJ-PHE indicator can be considered as a potential biomarker of drug-induced increased radioresistance (this was previously shown in our studies for betaleukin, indralin, and riboxin).
Key words: anti-radiation drugs, flagellin, X-radiation, mice, radioprotective efficacy, micronucleus test, polychromatophilic erythrocytes
For citation: Lisina NI, Romanova KYu, Sycheva LP, Rozhdestvensky LM. Comparative Evaluation of the Anti-Radiation Efficacy
of Flagellin by Survival and Micronucleus Test. Medical Radiology and Radiation Safety. 2021;66(4):13-17.
DOI: 10.12737/1024-6177-2021-66-4-13-17
References
1. Directive 2010/63/EU of the European Parliament and of the Council of the European Union on the protection of animals used for scientific purposes. Saint Petersburg: Rus-Lasa "NP association of specialists in working with laboratory animals" 2012, 48 p. (In Russian)
2. Guidelines for conducting preclinical studies of medicines. Part 1. M.: Grif and K. 2012. 944 p. (In Russian)
3. Heddle JA, Cimino MC, Hayashi M, et al. Micronuclei as an index of cytogenetic damage: past, present, and future. Environmental and Molecular Mutagenesis. 1991; 18: 277–291.
4. OECD Guideline for the testing of chemicals №474. Mammalian Erythrocyte Micronucleus Test. Adopted 21st July 1997. 10 p.
5. Sycheva LP, Lisina NI, Shchegoleva RA, Rozhdestvensky LM. Antimutagenic effect of anti-radiation drugs in an experiment on mice. Radiation biology. Radioecology.2019; 59(4):388–393. (In Russian)
6. Burdelya LG, KrivokrysenkoVI, Tallant TC, et al. An agonist of toll-lair receiver 5 has radioprotective activity in mouse and primate models. Sciepse 2008; 320. (5873): 226–230. (In Russian)
7. Krivokrysenko VN, Shakhov AN, Gudkov AV, Feinstein E. Identification of G-CSF and IL-6 as candidate biomarkers of GBLB502 efficacy as a medical radiation countermeasure. JPET Fast Forward. 2012 P. 1-46. DOI: 0.1124/jpet.112.196071. (In Russian)
8. Grebenyuk AN, Aksenov KV, Petrov AV, etc. Obtaining various variants of recombinant flagellin and evaluating their radioprotective effectiveness. Medical Academic. Journal. 2017; 43(3);75-80. (In Russian)
9. Murzina EV, Sofronov GA, Aksenova NV, etc. Anti-radiation properties of bacterial flagellin. Bulletin of the Russian Military Medical Academy. 2017; 36(2). Suppl 1: 242–243. (In Russian)
10. Murzina EV, Sofronov GA, Simbirtsev AS, et al. Evaluation of the radioprotective properties of recombinant flagellin when used separately or in combination with IL-1beta. Medical. Akademic. Journal. 2018; 18(3):77-84. (In Russian)
11. Murzina EV, Sofronov GA, Aksenova NV, et al. Experimental evaluation of the anti-radiation efficacy of recombinant flagellin. Bulletin of the Russian Military Medical Academy. 2018; 3: 122–128. (In Russian)
12. Murzina EV, Sofronov GA, Aksenova NV, et al. Biotechnological preparations promising for the development of new anti-radiation agents. The Messenger Grew. Bulletin of the Russian Military Medical Academy. 2017; 3: 133–136. (In Russian)
13. Sapozhnikov RYu, Khalimov Yu Sh, Legeza VI, etc. Preventive and curative efficacy of recombinant flagellin in acute radiation damage. Bulletin of the Russian Military Medical Academy, 2019; 67(3):141–144. (In Russian)
14. Lisina NI, Shchegoleva RA, Shlyakova TG, Zorin VV, Shkaev AE, Rozhdestvensky LM. Anti-radiation efficacy of flagellin in experiments on mie. Radiation biology. Radioecology.2019; 59(3):1–5. (In Russian)
15. Evaluation of the mutagenic activity of environmental factors in the cells of different mammalian organs by the micronucleus method. Methodological recommendations. Ed. Official. M., Interdepartmental Scientific Council for Ecology and Environmental Hygiene of the Russian Federation. 2001. p. 21.
16. Sycheva LP, Rozhdestvensky LM, Lisina NI, et al. Antimutagenic activity and hepatoprotective effect of anti-radiation drugs. Medical Genetics. 2020; 19(9): 81–82.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 16.03.2021.
Accepted for publication: 21.04.2021.